Pancreatic Cancer Research

Clinical trialPhase 1Recruiting

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.

Phase 1 First-in-Human, Dose Escalation and Dose Expansion Study of RYZ401, a Novel Radiopharmaceutical Therapy Labeled With Actinium-225, in Subjects With Neuroendocrine Tumors and Other Solid Tumors Expressing Somatostatin Receptors.

Outcome
Ongoing
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Start
3 December 2025
Expected end
April 2033
Enrollment
104 participants
Sites
15
Primary outcomes
Dose Escalation; Dose Expansion
Sponsor type
Industry
Results posted
No
Last update
3 November 2026

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected solid tumors expressing SSTRs.